Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MS&D's INDOCIN (INDOMETHACIN) SUPPOSITORIES TRADE PRICE IS $17.74

Executive Summary

MS&D's INDOCIN (INDOMETHACIN) SUPPOSITORIES TRADE PRICE IS $17.74 for a carton of 30, the firm said Sept. 7, the same day that it began distributing the drug. The suppository form of the drug cleared FDA Aug. 14. In announcing the product's availability, Merck stated that it is "the first suppository form of a Rx non-steroidal anti-inflammatory drug (NSAID) for the treatment of certain forms of arthritis." In the announcement Merck maintained that the suppository form provides a more rapid rate of absorption than capsules. Also, Merck said, there is some evidence that adverse gastric side effects may be reduced by the suppository dosing. The company said that the rectal suppositories "are particularly suited as an alternate dosage form for patients who cannot or will not take oral medication, and a supplement (i.e., nighttime) to the capsule form for the management of night pain and morning stiffness associated with rheumatoid arthritis and osteoarthritis." The new dosage form is emerging onto the U.S. market just as Merck is beginning to face generic competition for its oral indomethacin. Merck filed the NDA for the product in 1975. According to the company, the suppository form already accounts for approximately one third of Indocin sales worldwide, with percentages in major European markets ranging from 27% in Germany to a high of 76% in Spain. Suppositories now account for 30% of Canadian Indocin sales, the firm said. Like the capsule and sustained release form of the drug already available in the U.S., the Indocin suppository is indicated for the treatment of active stages of moderate to severe osteoarthritis and moderate to severe rheumatoid arthritis in patients not responding to an adequate trial of aspirin and rest. Similarly, it is indicated for moderate to severe ankylosing spondylitis, acute painful shoulder and acute gouty arthritis. In addition to the contraindication of Indocin for patients who have nasal polyps associated with angioedema or a bronchospastic reaction to aspirin or other NSAIDs, the suppository is contraindicated in patients with a history of proctitis or recent rectal bleeding.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel